Jim Cramer on Eli Lilly and Company (LLY): “You Don’t Sell Lilly” — “David Ricks Is a Visionary”

We recently published a list of Jim Cramer Nailed These 11 Stock Picks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses.

On Thursday, April 3rd, the host of Mad Money opened the most recent show by addressing the growing concerns surrounding the current tariff policies. He questioned the effectiveness of these tariffs as he asked:

“What’s the deal with these heavy-handed tariffs? Look, I’ve never been a dogmatic free trader. I believe in fair trade, a pretty fierce belief just so you know and we can only get that by lowering the boom on our trading partners who rip us off as a matter of policy.”

READ ALSO: Jim Cramer’s Thoughts on Liberation Day, Tariffs, and 17 Stocks to Watch Right Now, and 10 Stocks on Jim Cramer’s Radar Recently

Cramer explained that while he has always supported the idea of tariffs in principle, especially when they are part of a well-thought-out strategy, he expressed frustration over how the new trade regime is being executed. He said he was taken aback by how poorly the administration was rolling out these changes, which he felt lacked a clear and coherent plan. Cramer then pointed out what James Surowiecki, the author of The Wisdom of Crowds, said about how the White House is calculating tariffs.

“The White House simply took our trade deficit with each country and then divided it by that country’s exports to America. Then they cut that number in half to determine the tariff rate we’d be slapping on the country in question.”

Cramer noted that just hours later, an unnamed official from the White House confirmed this and  described it as “the sum of all unfair trade practices, the sum of all cheating.” Cramer called it ill-advised. Later in the day, President Trump made a statement suggesting that he might be open to reducing tariffs if presented with “phenomenal” offers. However, Cramer raised an important question: “Who determines what those offers are, and what do they even mean?” He admitted that he had no clear answer to that question.

“Here’s the bottom line: I wish I could get behind this new tariff regime because I’ve never been a free trader ever. But the White House doesn’t seem to understand what it’s trying to do and the not-really-reciprocal tariffs we got yesterday could do tremendous damage to the US economy, of course including the stock market, without changing the bad behavior of our trading partners. To me, this has become a lose-lose, which is very tough to accept because I wanted tariffs to change things, not to wreck things.”

Our Methodology

For this article, we compiled a list of 11 stocks that were discussed by Jim Cramer during Mad Money episodes that aired 1 year ago between April 5 and April 12. We then calculated their performance for the past 12 months, until April 2nd, 2025, market close. We have also included the hedge fund sentiment for the stocks, which we sourced from Insider Monkey’s Q4 2024 database of over 900 hedge funds. The stocks are listed in the order that Cramer mentioned them.

Please note that this article mentions Jim Cramer’s previous opinions and may not account for any changes to his opinions regarding the stocks that are mentioned. It is primarily an examination of how his previously provided opinions have panned out.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Jim Cramer on Eli Lilly and Company (LLY): “You Don’t Sell Lilly” — “David Ricks Is a Visionary”

Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 115

Eli Lilly and Company (NYSE:LLY), a pharmaceutical powerhouse, has dominated headlines for its blockbuster GLP-1 weight loss and diabetes treatments. Last year, when the stock briefly dipped, Cramer urged viewers to consider it a buying opportunity.

“Eli Lilly down 20 bucks. Why? The only news is good news; broke ground for a new $2.5 billion plant in Frankfurt, Germany to make Zepbound, their GLP-1 weight loss drug. Call me a buyer if the dust settles.”

Since that segment aired, shares have recovered and risen 7%, validating Cramer’s call and investor confidence in Eli Lilly’s pipeline and growth outlook.

Jim Cramer was asked about Eli Lilly and Company (NYSE:LLY) recently and he didn’t hold back in expressing his support for the company’s CEO and how high his conviction is on the stock. Here’s what he said on the 2nd of April:

“You don’t sell Lilly. Lilly’s got the solution that may be good for everything from Alzheimer’s to heart disease, kidney failure, liver problems, and right now, weight and diabetes. And that’s at GLP-1, and Lilly got the big lead. David Ricks is a visionary. We stay long that stock.”

“I think that Eli Lilly is probably one of the least tariffed, least dangerous stocks. It does have a high dollar amount, $818, but I remember what Ken Langone told us, he’s the greatest, greatest investor that I’ve ever dealt with. He says, own Eli Lilly, going to a trillion dollars… I am with Ken Langone.”

Overall, LLY ranks 5th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.